Fig. 5From: The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology studyThe results of molecular docking assay (MDA). A myricetin-GSK3B. B diosgenin-IL2. C vestitol-NR4A1Back to article page